Showing results (31-40 of 259) with videos related to
Sort By:
Pageof 26
The Lancet. Respiratory Medicine|December 19, 2017
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic studyChia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, et al.Oncology|October 1, 2023
Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint InhibitorsDerek De-Rui Huang, Bin-Chi Liao, Wei-Hsun Hsu, et al.Genes, Chromosomes & Cancer|August 15, 2018
Driver mutations of young lung adenocarcinoma patients with malignant pleural effusionShang-Gin Wu, Yi-Nan Liu, Chong-Jen Yu, et al.Clinical Lung Cancer|January 17, 2017
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung CancerYen-Ting Lin, Yi-Nan Liu, Shang-Gin Wu, et al.Cancers|January 27, 2021
Circulating Exosomal Integrin β3 Is Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial Irradiation for Brain Metastases: A Prospective Observational StudyGuann-Yiing Chen, Jason Chia-Hsien Cheng, Ya-Fang Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.Expert Review of Respiratory Medicine|December 9, 2016
New data on clinical decisions in NSCLC patients with uncommon EGFR mutationsTing-Hui Wu, Emily Han-Chung Hsiue, Jih-Hsiang Lee, et al.Future Oncology (London, England)|February 18, 2026
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancerRachel Woodford, Sally Lord, Tom John, et al.Translational Lung Cancer Research|February 9, 2026
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic reviewRoss A Soo, Darren Wan-Teck Lim, James Chih-Hsin Yang, et al.Clinical Drug Investigation|December 17, 2017
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKIHelen Mann, Frank Andersohn, Carolyn Bodnar, et al.Pageof 26